Risk of Bleeding in Patients Undergoing Coronary Interventions on Dual and Triple Therapies: A Retrospective Study

By Staff Writer

July 20, 2023

Dual antiplatelet therapy, a combination of aspirin and clopidogrel, prasugrel or ticagrelor, is recommended for up to 12 months for secondary prevention of ischemic events among people undergoing coronary interventions. However, real-world bleeding among populations exposed to different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens has not been previously quantified. The economic impact of bleeding events is poorly characterised, particularly for minor bleeding, as is their impact on health-related quality of life.

A retrospective population-based cohort study sheds light on the bleeding risks associated with dual antiplatelet therapy and triple therapy (including an anticoagulant) in patients following coronary interventions.

Findings indicate that the incidence of bleeding was 5% in coronary artery bypass graft patients, 10% in conservatively managed acute coronary syndrome patients, and 9% in emergency percutaneous coronary intervention patients, compared to a significantly higher 18% in those on triple therapy.

Interestingly, dual antiplatelet therapy, compared to aspirin alone, increased the hazards of bleeding and major adverse cardiovascular events in coronary artery bypass grafting and conservatively managed acute coronary syndrome patients.

Moreover, among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor (as opposed to clopidogrel) increased bleeding risks, but did not reduce major adverse cardiovascular events.

The study suggests that more potent dual antiplatelet therapy may increase bleeding risk without reducing major adverse cardiovascular events. These findings should be carefully considered by clinicians and decision-makers when recommending dual antiplatelet therapy.

There is still a need for prospective observational studies that provide high-quality data on outcomes and healthcare costs. A formal cost-effectiveness analysis could not be conducted due to the uncertainty surrounding the estimates for bleeding.

 

Reference url

Recent Posts

lenacapavir HIV prevention
      

Lenacapavir HIV Prevention: Approval and Access Strategy Updates

🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!

#SyenzaNews #globalhealth #healthcareInnovation

Africa health partnership
      

Strengthening Africa Health Partnership

🌍 Can collaboration redefine Africa’s health landscape?

A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.

Look into the details of this transformative partnership and its implications for the future of healthcare in the region!

#SyenzaNews #globalhealth #HealthcareInnovation

breast cancer Africa
    

Urgent Call for Enhanced Breast Cancer Africa Control Measures

🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?

A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.

Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.

#SyenzaNews #globalhealth #oncology #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.